Urology Today.net

Site updated at Thursday, 12 May 2016

Common Urological Problems


FDA Approves Xtandi for Late-Stage Castration-Resistant Prostate Cancer

The U.S. Food and Drug Administration today approved Xtandi (enzalutamide) to treat men with late-stage (metastatic) castration-resistant prostate cancer that has spread or recurred, even with medical or surgical therapy to minimize testosterone.

Approved for prostate cancer patients previously treated with docetaxel, another anti-cancer treatment, Xtandi was reviewed under the FDA’s priority review program.… FDA Approves Xtandi for Late-Stage Castration-Resistant Prostate Cancer   

johns hopkins university2 - prepucial stones1 - differential diagnosis1 - albuminuria2 - preemptive kidney transplantation1 - fluoroscopic imaging1 - collagen diseases1 - patient1 - mri scan1 - pelvic inflammatory disease2 - nephrogenesis1 - robot-assisted surgery1 - autism spectrum disorder1 - benign prostate tissue1 - clinical trials1 - dehydration1 - rectal carcinoid1 - urinary citrate1 - polyarteritis nodosa1 - significant incontinence6 - stone formation3 - cprs-r1 - prostate removal surgery1 - niddk1 - ralp1 - bladder calculi1 - kidney transplant15 - diabetes-related kidney failure1 - urinary drainage1 - gonococcal infection2 -